🎉 Founding Member Beta — Join our Discord and get 3 months of Pro free. Learn more →

Catherine Wood’s GENB Holdings & Trades

First Buy
Q1 2026
Duration Held
1 Quarters
Largest Add
Q1 2026
+498,408 Shares
Current Position
498,408 Shares
$6.23 M Value

Catherine Wood's GENB Position Overview

Catherine Wood (via Ark Investment Management LLC) currently holds 498,408 shares of Generate Biomedicines, Inc. (GENB) worth $6.23 M, representing 0.05% of the portfolio. First purchased in 2026-Q1, this recently established position has been held for 1 quarters.

Based on recent 13F filings, Catherine Wood has initiated a new position in GENB, representing a fresh investment thesis on this company. Insufficient history to summarize additions or reductions.

Analysis based on 13F filings available since 2013 Q2

Catherine Wood's Generate Biomedicines (GENB) Holding Value Over Time

Track share changes against reported price movement

Quarterly Generate Biomedicines (GENB) Trades by Catherine Wood

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q1 2026 +498,408 New Buy 498,408 $12.50

Catherine Wood's Generate Biomedicines Investment FAQs

Catherine Wood first purchased Generate Biomedicines, Inc. (GENB) in Q1 2026, acquiring 498,408 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Catherine Wood has held Generate Biomedicines, Inc. (GENB) for 1 quarters since Q1 2026.

Catherine Wood's largest addition to Generate Biomedicines, Inc. (GENB) was in Q1 2026, adding 498,408 shares worth $6.23 M.

According to the latest 13F filing for Q1 2026, Catherine Wood's firm, Ark Investment Management LLC, owns 498,408 shares of Generate Biomedicines, Inc. (GENB), valued at approximately $6.23 M.

As of the Q1 2026 filing, Generate Biomedicines, Inc. (GENB) represents approximately 0.05% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.

Catherine Wood's peak holding in Generate Biomedicines, Inc. (GENB) was 498,408 shares, as reported at the end of Q1 2026.